Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-1 Inhibitor Plus Chemotherapy With or Without Radiotherapy in Metastatic Esophageal Cancer
NCT06086457Phase 3Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Feb 2024
- Primary completion
- Jun 2026
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial (2 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Overall Survival at 33 months. Started Feb 2024; status: recruiting.
Beyond the preview
Go deeper on NCT06086457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06086457.